Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemo ...

The public has a right to know their risk when and if they choose to drink. Such labeling has precedents with that on tobacco.

The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...

CTA approval marks Anocca's transition to a clinical-stage company <li /> First-in-human VIDAR-1 trial begins with the deployment of AN ...